Sort by
Refine Your Search
-
of the REFINE-MS trial, a multi-centre, phase 3 study led by Professor Olga Ciccarelli and Professor Max Parmar at UCL. The trial aims to identify the optimal dosing frequency of ocrelizumab in patients with
Searches related to optimization
Enter an email to receive alerts for optimization positions